Omnicare (NYSE: OCR ): Q2 EPS of $0.91 beats by $0.01 . Revenue of $1.61B (+6.6% Y/Y) beats by $20M . Press Release Post your comment!
Omnicare continues to struggle with operating problems.
financial performance of the companies in our investment portfolio than we do their stock charts and in one instance, Omnicare , the largest supplier of pharmaceuticals to patients in nursing homes, delivered in spades. New management came in
Pharmerica, is contesting an offer from Omnicare , which itself is a Fund holding ..... is effectively managed. We find Omnicare ’s new management team to be impressive and estimate that the combination with Pharmerica would ..... 3%, PharMerica Corp. 0.1%, Omnicare , Inc. 0.7%, The TJX Cos
Omnicare OCR announced plans to purchase key rival ..... announced our plan to drop coverage of Omnicare , we will probably drop coverage of PharMerica ..... also suspending our credit rating for Omnicare in the wake of this deal. The $15 per
We are no longer providing equity research on Omnicare OCR . We provide broad coverage of more than 1,700 companies across more than 140 industries, and adjust our coverage as necessary based on client demand and investor interest.
Omnicare OCR reported solid second-quarter results ..... financial guidance for the year. While Omnicare is still in turnaround mode, we see signs ..... performance over the second half of the year. Omnicare increased revenue around 4% during the
setting its sights on industry giant Omnicare OCR . We thought PharMerica had some ..... advantages over the market leader, as Omnicare continued to alienate and lose ..... firm's success recently, with Omnicare now seeming to be the least of
Private equity firms have also been active in the purchase of smaller providers such as Trident Clinical Research and Omnicare CR in recent months, and it has been reported that PRA International is once again putting itself on the auction block
Omnicare has been party to a number of lawsuits alleging ..... competition continues to escalate, as Omnicare has lost market share to smaller independent ..... pharmacies willing to bid aggressively on price. Omnicare faces growing legal battles, as it has